Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price ...
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2025 Adj EPS guidance from $0.70-$0.75 to $0.75-$0.80 vs $0.77 analyst estimate. ...
Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate o...
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administra...
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the submission of a Bio...
